Multiple myeloma

Leukaemia

Multiple myeloma

Non-Hodgkin lymphoma

Hodgkin lymphoma

 

 

Cancer Cases

Cancer incidence rate refers to the number of new cancers cases occurring in a specified population during a given year, expressed as the number of cancer cases per 100,000 population.1 

In 2018, the UK ranked 2nd amongst the 31 European countries studied for the incidence of multiple myeloma, with 10 people in every 100,000 being diagnosed with the condition (ranging from 2 cases per 100,000 people in Bulgaria to 10 per 100,000 people in Italy).

The UK's incidence rate for this cancer type was higher than the European average of 8 cases per 100,000 people.

EU31

EU5

Downloads:

Note:

  • For this cancer type there is no information available on incidence at a country level for 1995

Reference for text:

1. National Cancer Institute. Cancer Incidence Rates. 

References for graphs:

Cancer Deaths

Cancer mortality rate refers to the number of deaths caused by cancer occurring in a specified population during a given year, expressed as the number of cancer deaths per 100,000 population.2

In 2018, the UK ranked 10th amongst the 31 European countries studied for the mortality of multiple myeloma, with 5 in every 100,000 people dying from the condition (ranging from 2 deaths per 100,000 people in Bulgaria to 7 per 100,000 people in Portugal).

The UK's mortality rate for this cancer type was similar to the European average.

EU31
EU5

Downloads:

Note:

  • For this cancer type there is no information available on mortality at a country level for 1995

Reference for text:

2. National Cancer Institute. Cancer Mortality Rates.

References for graphs:

Cancer Survival

Survival refers to the percentage of people that were diagnosed with cancer in a given year and who are still alive after a specified period of time (here defined as 5 years or more following diagnosis).3

Between 2010 and 2014, the UK ranked 13th amongst the 28 European countries studied for the 5 year survival post-diagnosis of blood cancers, with 65% of people surviving 5 years or more after being diagnosed with these cancer types (ranging from 40% survival in Romania to 72% in Switzerland).

EU31

EU5

Downloads:

Notes:

  • There is no country level data for these cancer types between 1995 and 1999
  • There is no European average for 5-year survival because data for Greece, Hungary and Luxembourg is lacking
  • Survival data was only collected for leukaemia, Non-Hodgkin lymphoma, Hodgkin lymphoma and multiple myeloma for all countries
  • The latest data collected by IHE was for the 2010-2014 5-year period

Reference for text:

3. Hofmarcher, T et al. (2019) Comparator Report on Cancer in Europe 2019 - Disease Burden, Costs and Access to Medicines. IHE Report 2019:7. IHE: Lund, Sweden

References for graphs:

Uptake of Cancer Medicines

The uptake of multiple myeloma medicines was analysed as sales in standard weekly doses (SWD) per cancer case in individual countries and is displayed in the below graph cumulatively.3

In 2018, the UK's cumulative uptake of multiple myeloma medicines analysed ranked 14th amongst the 26 European countries studied.

The UK's cumulative uptake for multiple myeloma medicines was the lowest amongst the other EU5 countries – Italy, Germany, France and Spain.

EU31
EU5

Downloads:

Notes:

  • The multiple myeloma medicines analysed by IHE were bortezomib, carfilzomib, daratumumab, lenalidomide and pomalidomide
  • IHE selected a range of medicines launched between 2005-2015 that were identified by oncologists to represent accepted standard treatments and had high volumes of use across European countries. This selection process led to the variation in the number of individual medicines selected for each tumour type. Data was then collected from each country to highlight variation in volumes used as presented in these charts

Reference for text and graphs:

Last modified: 22 April 2024

Last reviewed: 22 April 2024